Specific to asthma, it was previously shown that SP-A function is defective, which could arise from genetic variation.1–3 Hence, a 10-amino acid (AA) active region of SP-A2 has been identified that significantly reduces phenotypes associated with asthma in human cells and in murine models.4 This 10-AA (1.25 kDa) size SP-A peptide is an ideal candidate to package into an inhaler for airway delivery. This evidence concerns the gene SFTPA2 and asthma.